These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34881062)

  • 21. Testosterone recovery after androgen deprivation therapy.
    Ho AY; Li EV; Bennett R; Suk-Ouichai C; Kumar SKSR; Neill C; Li Y; Schaeffer EM; Morgans AK; Patel HD; Ross AE
    Urol Oncol; 2025 Jan; 43(1):65.e1-65.e8. PubMed ID: 39242300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
    Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
    World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of Advanced Prostate Cancer With Relugolix: Illustrative Case Scenarios From an Advanced Practice Provider Perspective.
    Thorley J; Stephen S
    J Adv Pract Oncol; 2024 Jan; 15(1):43-55. PubMed ID: 39119081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer.
    Adekunle OA; Seoane-Vazquez E; Brown LM
    J Am Pharm Assoc (2003); 2023; 63(3):817-824.e3. PubMed ID: 36653276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
    Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
    JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model.
    Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A
    Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
    Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
    Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
    Kasparian S; Wei O; Tsai NC; Palmer J; Pal S; Lyou Y; Dorff T
    Oncologist; 2023 Aug; 28(8):699-705. PubMed ID: 36888587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Degarelix acetate for the treatment of prostate cancer.
    Klotz L
    Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.